Correspondence 0001683168-22-008045 from CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc.
Date: Nov. 28, 2022 · CIK: 0001729427 · Accession: 0001683168-22-008045
AI Filing Summary & Sentiment
File numbers found in text: 333-267975
Letter
CNS Pharmaceuticals, Inc.
2100 West Loop South, Suite 900
Houston, TX 77027
November 28, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Attention: Doris Stacey Gama
Re: CNS Pharmaceuticals, Inc.
Registration Statement on Form S-1
Registration No. 333-267975
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 1:00 P.M. (Eastern Time) on November 29, 2022, or as soon thereafter as possible on such date.
Very truly yours,
CNS Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
CNS Pharmaceuticals, Inc.
2100 West Loop South, Suite 900
Houston, TX 77027
November 28, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Attention: Doris Stacey Gama
Re:
CNS Pharmaceuticals, Inc.
Registration Statement on Form S-1
Registration No. 333-267975
Ladies and Gentlemen:
Pursuant to Rule 461 of
the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby respectfully
requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective
at 1:00 P.M. (Eastern Time) on November 29, 2022, or as soon thereafter as possible on such date.
Very truly yours,
CNS Pharmaceuticals, Inc.
By:
/s/Christopher Downs
Name: Christopher Downs
Title: Chief Financial Officer